Viral and Host Factors in the Transmission and Pathogenesis of HIV

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2000-07-31

Study Completion Date

2019-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To study the collection of blood from individuals known to be at high risk for HIV-infection or who have been recently infected with HIV.

The data collected are used for diagnostic, prognostic and management decisions as outlined by current HIV-1 Treatment Guidelines.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV Infection

NCT00614458

HIV Infections

TERMINATED PHASE2

Raltegravir as Early Therapy in African-Americans Living With HIV Study

NCT00667433

HIV Infections

COMPLETED PHASE1

Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery

NCT00562510

HIV Infections

TERMINATED PHASE3

Ex Vivo Characterization and Targeting of the Latent HIV Infected Reservoir to Cure HIV

NCT05215704

HIV Infections HIV-1-infection HIV-2 Infection

RECRUITING

Observational Study of Treated and Untreated Acute and Early HIV-1 Infection

NCT00219934

HIV Infections

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This phlebotomy protocol permits the collection of blood from individuals known to be at high risk for HIV-infection or who have been recently infected with HIV.

Participants will have from 10 to 60 ml (approximately 1 to 4 tablespoons) of blood drawn for one or all of the following tests:

* T cell subset enumeration
* Serologic reactivity with HIV antigens
* Viral load assays by bDNA, PCR, or RT-PCR
* Routine Laboratory assessments (chemistries, liver function tests, hepatitis serology, RPR)
* HIV-1 Resistance Testing

These data are used for diagnostic, prognostic and management decisions as outlined by current HIV-1 Treatment Guidelines

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

high risk

Blood draw from individuals known to be or at high risk for HIV-infection

blood draw

Intervention Type OTHER

* T cell subset enumeration
* Serologic reactivity with HIV antigens
* Viral load assays by bDNA, PCR, or RT-PCR
* Routine Laboratory assessments (chemistries, liver function tests, hepatitis serology, RPR)
* HIV-1 Resistance Testing

diagnosed

Blood draw f rom individuals diagnosed with HIV infection

blood draw

Intervention Type OTHER

* T cell subset enumeration
* Serologic reactivity with HIV antigens
* Viral load assays by bDNA, PCR, or RT-PCR
* Routine Laboratory assessments (chemistries, liver function tests, hepatitis serology, RPR)
* HIV-1 Resistance Testing

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood draw

* T cell subset enumeration
* Serologic reactivity with HIV antigens
* Viral load assays by bDNA, PCR, or RT-PCR
* Routine Laboratory assessments (chemistries, liver function tests, hepatitis serology, RPR)
* HIV-1 Resistance Testing

Intervention Type OTHER